Mind Medicine (MindMed) Inc. (MNMD) 10-Year Financial Performance & Capital Metrics

MNMD • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutMind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.Show more

Revenue $0
EBITDA -$103M -14.0%
Net Income -$109M -13.5%
EPS (Diluted) -0.15 +93.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -68.01% +18.6%
ROIC -
Debt/Equity 0.09 -49.9%
Interest Coverage -45.52 +55.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 89 (top 11%)
✓Trading near 52-week high

✗Weaknesses

✗Shares diluted 100.0% in last year
✗Expensive at 44.9x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-71.88%

EPS CAGR

10Y-

5Y-

3Y-

TTM-2.96%

ROCE

10Y Avg-52.68%

5Y Avg-68.17%

3Y Avg-59.55%

Latest-58.45%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Aug 2015	Aug 2016	Aug 2017	Aug 2018	Aug 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	5.5K	6.68K	6.68K	0	0	0	3.16M	527K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	-5.5K	-6.68K	-6.68K	0	0	0	-3.16M	-527K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-0.21%	-0%	1%	-	-	-	0.83%
Operating Expenses+	94.55K	111.25K	1.23M	855.26K	461.5K	33.03M	93.85M	66.33M	90.7M	103.39M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	94.55K	111.25K	1.23M	855.26K	461.5K	14.4M	59.06M	30.16M	41.74M	38.62M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	0	0	0	0	0	18.63M	34.79M	36.17M	48.96M	65.3M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	-527K
Operating Income+	-94.55K	-111.25K	-1.24M	-861.94K	-468.18K	-33.03M	-93.85M	-66.33M	-93.87M	-103.92M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-0.18%	-10.1%	0.3%	0.46%	-69.55%	-1.84%	0.29%	-0.42%	-0.11%
EBITDA+	-94.55K	-111.25K	-1.23M	-855.26K	-461.5K	-32.82M	-91.24M	-63.15M	-90.7M	-103.39M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-0.18%	-10.05%	0.3%	0.46%	-70.12%	-1.78%	0.31%	-0.44%	-0.14%
D&A (Non-Cash Add-back)	0	0	5.5K	6.68K	6.68K	206.3K	2.62M	3.18M	3.16M	527K
EBIT	-92.66K	-179.9K	-1.51M	-857.94K	-1.12M	-33.77M	-93.85M	-66.33M	-95.73M	-106.4M
Net Interest Income+	0	0	0	0	0	-164K	-359K	0	4.66M	9.28M
Interest Income	1.9K	1.2K	8.4K	4K	0	0	0	1.5M	5.58M	11.56M
Interest Expense	0	0	0	0	0	164K	359K	1.5M	920K	2.28M
Other Income/Expense	1.89K	-68.65K	8.4K	4K	-647.63K	-907K	-339K	9.54M	-1.87M	-4.76M
Pretax Income+	-92.66K	-179.9K	-1.23M	-857.94K	-1.12M	-33.94M	-94.19M	-56.8M	-95.73M	-108.68M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	-2	-2	-4	0	-1.16M	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	0.99%	1%	1%	1%
Net Income+	-92.66K	-179.9K	-1.23M	-857.94K	-1.12M	-34.1M	-93.04M	-56.8M	-95.73M	-108.68M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	-0.94%	-5.82%	0.3%	-0.3%	-29.56%	-1.73%	0.39%	-0.69%	-0.14%
Net Income (Continuing)	-92.66K	-179.9K	-1.23M	-857.94K	-1.12M	-33.94M	-93.04M	-56.8M	-95.73M	-108.68M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.17	-2.24	-4.85	-2.74	-2.94	-1.92	-3.40	-1.53	-2.44	-0.15
EPS Growth %	-	-0.91%	-1.17%	0.44%	-0.07%	0.35%	-0.77%	0.55%	-0.59%	0.94%
EPS (Basic)	-1.17	-2.24	-4.85	-2.74	-2.94	-1.92	-3.40	-1.53	-2.44	-1.54
Diluted Shares Outstanding	79K	80.42K	252.82K	312.55K	379.41K	17.75M	27.38M	30.86M	39.16M	704.61M
Basic Shares Outstanding	79K	80.42K	252.82K	312.55K	379.41K	17.75M	27.38M	30.86M	39.16M	70.46M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Aug 2015	Aug 2016	Aug 2017	Aug 2018	Aug 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	186.4K	136.19K	1.77M	198.63K	2.94M	81.52M	137.22M	146.06M	103.87M	281.62M
Cash & Short-Term Investments	184.09K	129.33K	1.69M	154.79K	17.93K	80.09M	133.54M	142.14M	99.7M	273.74M
Cash Only	4.62K	10.96K	3.98K	154.79K	17.93K	80.09M	133.54M	142.14M	99.7M	273.74M
Short-Term Investments	179.47K	118.37K	1.69M	0	0	0	0	0	0	0
Accounts Receivable	359	4.88K	10.28K	8.24K	5.08K	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	1	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	0.05	-	-	-	-	-	-
Other Current Assets	0	1.98K	0	0	2.91M	0	0	0	4.17M	7.88M
Total Non-Current Assets+	105.25K	66.56K	2.26M	3.33M	0	0	26.79M	23.94M	20.67M	20.53M
Property, Plant & Equipment	0	0	70.5K	63.88K	0	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	19.92M	19.92M	19.92M	19.92M
Intangible Assets	0	0	0	0	0	0	6.87M	3.69M	527K	0
Long-Term Investments	0	0	69.99K	136K	0	0	0	0	0	0
Other Non-Current Assets	105.25K	66.56K	2.12M	3.13M	0	0	0	331K	224K	613K
Total Assets+	291.66K	202.75K	4.03M	3.53M	2.94M	81.52M	164M	169.99M	124.54M	302.15M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-	-0.3%	18.86%	-0.12%	-0.17%	26.76%	1.01%	0.04%	-0.27%	1.43%
Total Current Liabilities+	7.49K	75.47K	80.44K	8.23K	198.96K	3.01M	10.41M	17.89M	32.25M	38.85M
Accounts Payable	0	0	0	0	0	2.02M	4.18M	2.11M	4.14M	2.01M
Days Payables Outstanding	-	-	-	-	-	-	-	-	477.43	1.39K
Short-Term Debt	0	0	15.74K	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	7.49K	75.47K	64.7K	8.23K	198.96K	-462K	2.29M	13.03M	20.74M	30.41M
Current Ratio	24.90x	1.80x	22.03x	24.14x	14.76x	27.10x	13.18x	8.16x	3.22x	7.25x
Quick Ratio	24.90x	1.80x	22.03x	24.14x	14.76x	27.10x	13.18x	8.16x	3.22x	7.25x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	0	2.64M	1.93M	1.18M	14.16M	21.85M
Long-Term Debt	0	0	0	0	0	0	0	0	14.13M	21.85M
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	2.64M	1.93M	1.18M	32K	0
Total Liabilities	7.49K	75.47K	80.44K	8.23K	198.96K	5.65M	12.34M	19.08M	46.41M	60.7M
Total Debt+	0	0	15.74K	0	0	0	0	72K	14.13M	21.85M
Net Debt	-4.62K	-10.96K	11.77K	-154.79K	-17.93K	-80.09M	-133.54M	-142.07M	-85.58M	-251.89M
Debt / Equity	-	-	0.00x	-	-	-	-	0.00x	0.18x	0.09x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-201.40x	-261.43x	-44.37x	-102.03x	-45.52x
Total Equity+	284.17K	127.28K	3.95M	3.52M	2.74M	75.87M	151.66M	150.92M	78.13M	241.45M
Equity Growth %	-	-0.55%	30.01%	-0.11%	-0.22%	26.71%	1%	-0%	-0.48%	2.09%
Book Value per Share	3.60	1.58	15.61	11.28	7.22	4.27	5.54	4.89	2.00	0.34
Total Shareholders' Equity	284.17K	127.28K	3.95M	3.52M	2.74M	75.87M	151.66M	150.92M	78.13M	241.45M
Common Stock	560K	567.88K	5.16M	5.32M	5.56M	0	0	0	0	0
Retained Earnings	-313.4K	-499.71K	-1.81M	-2.59M	-3.65M	-44.64M	-137.67M	-194.47M	-290.2M	-398.88M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	-34	-41.38K	19.14K	34.69K	284K	1.05M	627K	343K	819K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Aug 2015	Aug 2016	Aug 2017	Aug 2018	Aug 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-46.56K	-26.64K	-665.98K	-722.45K	-208.12K	-23.6M	-45.82M	-50.14M	-64.36M	-79.13M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	0.43%	-24%	-0.08%	0.71%	-112.38%	-0.94%	-0.09%	-0.28%	-0.23%
Net Income	-92.66K	-179.9K	-1.23M	-857.94K	-1.12M	-33.94M	-93.04M	-56.8M	-95.73M	-108.68M
Depreciation & Amortization	0	0	5.5K	6.68K	6.68K	0	2.62M	3.18M	3.16M	527K
Stock-Based Compensation	0	0	0	0	0	7.41M	42.72M	13.71M	15.49M	16.91M
Deferred Taxes	0	0	0	0	0	0	-1.16M	0	-2.02M	0
Other Non-Cash Items	41.44K	95.11K	652.92K	160.96K	703.52K	873K	1.16M	-6.45M	8.46M	15.45M
Working Capital Changes	4.76K	62.62K	-81.76K	-20.46K	207.83K	2.06M	1.88M	-3.78M	6.28M	-3.34M
Change in Receivables	-98	-4.46K	-4.91K	1.68K	3.02K	-13K	0	0	0	0
Change in Inventory	0	0	0	0	0	13K	0	0	0	0
Change in Payables	0	0	0	0	0	544K	1.28M	-2.06M	2.02M	-2.13M
Cash from Investing+	41.86K	32.83K	-3.67M	541.34K	-213.15K	0	-297K	0	0	0
Capital Expenditures	0	-30.1K	-2.15M	-1.04M	-313.46K	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	30.44K	0	100.3K	0	0	0	0	0
Cash from Financing+	0	-331	4.35M	312.05K	288.36K	96.7M	98.82M	59.05M	21.85M	253.2M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	-331	0	0	0	24.71M	16.9M	16.75M	163K	-7.66M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-46.56K	-56.73K	-2.82M	-1.77M	-521.58K	-23.6M	-45.82M	-50.14M	-64.36M	-79.13M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-	-0.22%	-48.63%	0.37%	0.7%	-44.24%	-0.94%	-0.09%	-0.28%	-0.23%
FCF per Share	-0.59	-0.71	-11.14	-5.65	-1.37	-1.33	-1.67	-1.62	-1.64	-0.11
FCF Conversion (FCF/Net Income)	0.50x	0.15x	0.54x	0.84x	0.19x	0.69x	0.49x	0.88x	0.67x	0.73x
Interest Paid	0	0	0	0	0	0	0	0	0	2.22M
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-32.61%	-87.45%	-60.22%	-22.96%	-35.63%	-86.76%	-81.78%	-37.54%	-83.59%	-68.01%
Return on Invested Capital (ROIC)	-25.37%	-42.15%	-45.46%	-17.64%	-11.53%	-	-1012.89%	-368.89%	-10014.15%	-
Debt / Equity	-	-	0.00x	-	-	-	-	0.00x	0.18x	0.09x
Interest Coverage	-	-	-	-	-	-201.40x	-261.43x	-44.37x	-102.03x	-45.52x
FCF Conversion	0.50x	0.15x	0.54x	0.84x	0.19x	0.69x	0.49x	0.88x	0.67x	0.73x

Frequently Asked Questions

Growth & Financials

Mind Medicine (MindMed) Inc. (MNMD) grew revenue by 0.0% over the past year. Growth has been modest.

Mind Medicine (MindMed) Inc. (MNMD) reported a net loss of $168.1M for fiscal year 2024.

Dividend & Returns

Mind Medicine (MindMed) Inc. (MNMD) has a return on equity (ROE) of -68.0%. Negative ROE indicates the company is unprofitable.

Mind Medicine (MindMed) Inc. (MNMD) had negative free cash flow of $84.4M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Mind Medicine (MindMed) Inc. (MNMD) 10-Year Financial Performance & Capital Metrics

MNMD • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

Revenue $0
EBITDA -$103M -14.0%
Net Income -$109M -13.5%
EPS (Diluted) -0.15 +93.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -68.01% +18.6%
ROIC -
Debt/Equity 0.09 -49.9%
Interest Coverage -45.52 +55.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 89 (top 11%)
✓Trading near 52-week high

✗Weaknesses

✗Shares diluted 100.0% in last year
✗Expensive at 44.9x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-71.88%

EPS CAGR

10Y-

5Y-

3Y-

TTM-2.96%

ROCE

10Y Avg-52.68%

5Y Avg-68.17%

3Y Avg-59.55%

Latest-58.45%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Aug 2015	Aug 2016	Aug 2017	Aug 2018	Aug 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	5.5K	6.68K	6.68K	0	0	0	3.16M	527K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	-5.5K	-6.68K	-6.68K	0	0	0	-3.16M	-527K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-0.21%	-0%	1%	-	-	-	0.83%
Operating Expenses+	94.55K	111.25K	1.23M	855.26K	461.5K	33.03M	93.85M	66.33M	90.7M	103.39M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	94.55K	111.25K	1.23M	855.26K	461.5K	14.4M	59.06M	30.16M	41.74M	38.62M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	0	0	0	0	0	18.63M	34.79M	36.17M	48.96M	65.3M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	-527K
Operating Income+	-94.55K	-111.25K	-1.24M	-861.94K	-468.18K	-33.03M	-93.85M	-66.33M	-93.87M	-103.92M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-0.18%	-10.1%	0.3%	0.46%	-69.55%	-1.84%	0.29%	-0.42%	-0.11%
EBITDA+	-94.55K	-111.25K	-1.23M	-855.26K	-461.5K	-32.82M	-91.24M	-63.15M	-90.7M	-103.39M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-0.18%	-10.05%	0.3%	0.46%	-70.12%	-1.78%	0.31%	-0.44%	-0.14%
D&A (Non-Cash Add-back)	0	0	5.5K	6.68K	6.68K	206.3K	2.62M	3.18M	3.16M	527K
EBIT	-92.66K	-179.9K	-1.51M	-857.94K	-1.12M	-33.77M	-93.85M	-66.33M	-95.73M	-106.4M
Net Interest Income+	0	0	0	0	0	-164K	-359K	0	4.66M	9.28M
Interest Income	1.9K	1.2K	8.4K	4K	0	0	0	1.5M	5.58M	11.56M
Interest Expense	0	0	0	0	0	164K	359K	1.5M	920K	2.28M
Other Income/Expense	1.89K	-68.65K	8.4K	4K	-647.63K	-907K	-339K	9.54M	-1.87M	-4.76M
Pretax Income+	-92.66K	-179.9K	-1.23M	-857.94K	-1.12M	-33.94M	-94.19M	-56.8M	-95.73M	-108.68M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	-2	-2	-4	0	-1.16M	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	0.99%	1%	1%	1%
Net Income+	-92.66K	-179.9K	-1.23M	-857.94K	-1.12M	-34.1M	-93.04M	-56.8M	-95.73M	-108.68M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	-0.94%	-5.82%	0.3%	-0.3%	-29.56%	-1.73%	0.39%	-0.69%	-0.14%
Net Income (Continuing)	-92.66K	-179.9K	-1.23M	-857.94K	-1.12M	-33.94M	-93.04M	-56.8M	-95.73M	-108.68M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.17	-2.24	-4.85	-2.74	-2.94	-1.92	-3.40	-1.53	-2.44	-0.15
EPS Growth %	-	-0.91%	-1.17%	0.44%	-0.07%	0.35%	-0.77%	0.55%	-0.59%	0.94%
EPS (Basic)	-1.17	-2.24	-4.85	-2.74	-2.94	-1.92	-3.40	-1.53	-2.44	-1.54
Diluted Shares Outstanding	79K	80.42K	252.82K	312.55K	379.41K	17.75M	27.38M	30.86M	39.16M	704.61M
Basic Shares Outstanding	79K	80.42K	252.82K	312.55K	379.41K	17.75M	27.38M	30.86M	39.16M	70.46M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Aug 2015	Aug 2016	Aug 2017	Aug 2018	Aug 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	186.4K	136.19K	1.77M	198.63K	2.94M	81.52M	137.22M	146.06M	103.87M	281.62M
Cash & Short-Term Investments	184.09K	129.33K	1.69M	154.79K	17.93K	80.09M	133.54M	142.14M	99.7M	273.74M
Cash Only	4.62K	10.96K	3.98K	154.79K	17.93K	80.09M	133.54M	142.14M	99.7M	273.74M
Short-Term Investments	179.47K	118.37K	1.69M	0	0	0	0	0	0	0
Accounts Receivable	359	4.88K	10.28K	8.24K	5.08K	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	1	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	0.05	-	-	-	-	-	-
Other Current Assets	0	1.98K	0	0	2.91M	0	0	0	4.17M	7.88M
Total Non-Current Assets+	105.25K	66.56K	2.26M	3.33M	0	0	26.79M	23.94M	20.67M	20.53M
Property, Plant & Equipment	0	0	70.5K	63.88K	0	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	19.92M	19.92M	19.92M	19.92M
Intangible Assets	0	0	0	0	0	0	6.87M	3.69M	527K	0
Long-Term Investments	0	0	69.99K	136K	0	0	0	0	0	0
Other Non-Current Assets	105.25K	66.56K	2.12M	3.13M	0	0	0	331K	224K	613K
Total Assets+	291.66K	202.75K	4.03M	3.53M	2.94M	81.52M	164M	169.99M	124.54M	302.15M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-	-0.3%	18.86%	-0.12%	-0.17%	26.76%	1.01%	0.04%	-0.27%	1.43%
Total Current Liabilities+	7.49K	75.47K	80.44K	8.23K	198.96K	3.01M	10.41M	17.89M	32.25M	38.85M
Accounts Payable	0	0	0	0	0	2.02M	4.18M	2.11M	4.14M	2.01M
Days Payables Outstanding	-	-	-	-	-	-	-	-	477.43	1.39K
Short-Term Debt	0	0	15.74K	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	7.49K	75.47K	64.7K	8.23K	198.96K	-462K	2.29M	13.03M	20.74M	30.41M
Current Ratio	24.90x	1.80x	22.03x	24.14x	14.76x	27.10x	13.18x	8.16x	3.22x	7.25x
Quick Ratio	24.90x	1.80x	22.03x	24.14x	14.76x	27.10x	13.18x	8.16x	3.22x	7.25x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	0	2.64M	1.93M	1.18M	14.16M	21.85M
Long-Term Debt	0	0	0	0	0	0	0	0	14.13M	21.85M
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	2.64M	1.93M	1.18M	32K	0
Total Liabilities	7.49K	75.47K	80.44K	8.23K	198.96K	5.65M	12.34M	19.08M	46.41M	60.7M
Total Debt+	0	0	15.74K	0	0	0	0	72K	14.13M	21.85M
Net Debt	-4.62K	-10.96K	11.77K	-154.79K	-17.93K	-80.09M	-133.54M	-142.07M	-85.58M	-251.89M
Debt / Equity	-	-	0.00x	-	-	-	-	0.00x	0.18x	0.09x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-201.40x	-261.43x	-44.37x	-102.03x	-45.52x
Total Equity+	284.17K	127.28K	3.95M	3.52M	2.74M	75.87M	151.66M	150.92M	78.13M	241.45M
Equity Growth %	-	-0.55%	30.01%	-0.11%	-0.22%	26.71%	1%	-0%	-0.48%	2.09%
Book Value per Share	3.60	1.58	15.61	11.28	7.22	4.27	5.54	4.89	2.00	0.34
Total Shareholders' Equity	284.17K	127.28K	3.95M	3.52M	2.74M	75.87M	151.66M	150.92M	78.13M	241.45M
Common Stock	560K	567.88K	5.16M	5.32M	5.56M	0	0	0	0	0
Retained Earnings	-313.4K	-499.71K	-1.81M	-2.59M	-3.65M	-44.64M	-137.67M	-194.47M	-290.2M	-398.88M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	-34	-41.38K	19.14K	34.69K	284K	1.05M	627K	343K	819K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Aug 2015	Aug 2016	Aug 2017	Aug 2018	Aug 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-46.56K	-26.64K	-665.98K	-722.45K	-208.12K	-23.6M	-45.82M	-50.14M	-64.36M	-79.13M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	0.43%	-24%	-0.08%	0.71%	-112.38%	-0.94%	-0.09%	-0.28%	-0.23%
Net Income	-92.66K	-179.9K	-1.23M	-857.94K	-1.12M	-33.94M	-93.04M	-56.8M	-95.73M	-108.68M
Depreciation & Amortization	0	0	5.5K	6.68K	6.68K	0	2.62M	3.18M	3.16M	527K
Stock-Based Compensation	0	0	0	0	0	7.41M	42.72M	13.71M	15.49M	16.91M
Deferred Taxes	0	0	0	0	0	0	-1.16M	0	-2.02M	0
Other Non-Cash Items	41.44K	95.11K	652.92K	160.96K	703.52K	873K	1.16M	-6.45M	8.46M	15.45M
Working Capital Changes	4.76K	62.62K	-81.76K	-20.46K	207.83K	2.06M	1.88M	-3.78M	6.28M	-3.34M
Change in Receivables	-98	-4.46K	-4.91K	1.68K	3.02K	-13K	0	0	0	0
Change in Inventory	0	0	0	0	0	13K	0	0	0	0
Change in Payables	0	0	0	0	0	544K	1.28M	-2.06M	2.02M	-2.13M
Cash from Investing+	41.86K	32.83K	-3.67M	541.34K	-213.15K	0	-297K	0	0	0
Capital Expenditures	0	-30.1K	-2.15M	-1.04M	-313.46K	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	30.44K	0	100.3K	0	0	0	0	0
Cash from Financing+	0	-331	4.35M	312.05K	288.36K	96.7M	98.82M	59.05M	21.85M	253.2M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	-331	0	0	0	24.71M	16.9M	16.75M	163K	-7.66M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-46.56K	-56.73K	-2.82M	-1.77M	-521.58K	-23.6M	-45.82M	-50.14M	-64.36M	-79.13M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-	-0.22%	-48.63%	0.37%	0.7%	-44.24%	-0.94%	-0.09%	-0.28%	-0.23%
FCF per Share	-0.59	-0.71	-11.14	-5.65	-1.37	-1.33	-1.67	-1.62	-1.64	-0.11
FCF Conversion (FCF/Net Income)	0.50x	0.15x	0.54x	0.84x	0.19x	0.69x	0.49x	0.88x	0.67x	0.73x
Interest Paid	0	0	0	0	0	0	0	0	0	2.22M
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-32.61%	-87.45%	-60.22%	-22.96%	-35.63%	-86.76%	-81.78%	-37.54%	-83.59%	-68.01%
Return on Invested Capital (ROIC)	-25.37%	-42.15%	-45.46%	-17.64%	-11.53%	-	-1012.89%	-368.89%	-10014.15%	-
Debt / Equity	-	-	0.00x	-	-	-	-	0.00x	0.18x	0.09x
Interest Coverage	-	-	-	-	-	-201.40x	-261.43x	-44.37x	-102.03x	-45.52x
FCF Conversion	0.50x	0.15x	0.54x	0.84x	0.19x	0.69x	0.49x	0.88x	0.67x	0.73x

Frequently Asked Questions

Growth & Financials

Mind Medicine (MindMed) Inc. (MNMD) grew revenue by 0.0% over the past year. Growth has been modest.

Mind Medicine (MindMed) Inc. (MNMD) reported a net loss of $168.1M for fiscal year 2024.

Dividend & Returns

Mind Medicine (MindMed) Inc. (MNMD) has a return on equity (ROE) of -68.0%. Negative ROE indicates the company is unprofitable.

Mind Medicine (MindMed) Inc. (MNMD) had negative free cash flow of $84.4M in fiscal year 2024, likely due to heavy capital investments.